Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients

Liver International

Volumn 34, Issue 7, 2014, Pages

  Al Qahtani, Ahmed A ^a,d   Al Anazi, Mashael R ^a   Abdo, Ayman A ^b,d   Sanai, Faisal M ^c,d   Al Hamoudi, Waleed K ^b,d   Alswat, Khalid A ^b,d   Al Ashgar, Hamad I ^b   Khalaf, Nisreen Z ^a   Viswan, Nisha A ^a   Al Ahdal, Mohammed N ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cirrhosis; HBV; HCC; IL28B; Polymorphism; Saudi Arabia

Indexed keywords

IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

DISEASE COURSE; GENE FREQUENCY; GENETIC VARIABILITY; GENETICS; GENOTYPE; HAPLOTYPE; HEPATITIS B, CHRONIC; HUMAN; RISK; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE PROGRESSION; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SAUDI ARABIA;

EID: 84904514899     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12347     Document Type: Article

References (58)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
2. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993; 104: 955-63.
3. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21, vii.
4. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.
5. Lok AS, Mcmahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
6. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
7. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401.
8. Tran TT. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol (N Y) 2011; 7: 511-6.
9. Wiersma ST, Mcmahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011; 31: 755-61.
10. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.
11. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010; 15(Suppl 3): 25-33.
12. Giani G, Chiaramonte M, Pasini CV, Fagiolo U, Naccarato R. Hepatitis B surface antigenemia and HLA antigens. N Engl J Med 1979; 300: 1056.
13. Hillis WD, Hillis A, Bias WB, Walker WG. Associations of hepatitis B surface antigenemia with HLA locus B specificities. N Engl J Med 1977; 296: 1310-4.
14. Jagielski P, Sotnik D. HLA antigens in asymptomatic carriers of HBs antigen and in carriers of anti-HBs antibodies. Arch Immunol Ther Exp (Warsz) 1978; 26: 207-12.
15. Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012; 55: 1426-31.
16. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-5.
17. Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012; 8: e1002791.
18. Mbarek H, Ochi H, Urabe Y, et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 2011; 20: 3884-92.
19. Nishida N, Sawai H, Matsuura K, et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE 2012; 7: e39175.
20. Al-Qahtani A, Al-Ahdal M, Abdo A, et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 2012; 84: 1353-9.
21. Shi KQ, Cai XH, Xiao DD, et al. Tumour necrosis factor-alpha-857T allele reduces the risk of hepatitis B virus infection in an Asian population. J Viral Hepat 2012; 19: e66-72.
22. Zheng MH, Xiao DD, Lin XF, et al. The tumour necrosis factor-alpha-238A allele increases the risk of chronic HBV infection in European populations. J Viral Hepat 2012; 19: e11-7.
23. Zhang TC, Pan FM, Zhang LZ, et al. A meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population. Infection 2011; 39: 21-7.
24. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-93.
25. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
26. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
27. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
28. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45, 45 e1-7.
29. Donnelly RP, Dickensheets H, O'brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 2011; 32: 443-50.
30. Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-9.
31. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors 2009; 35: 82-7.
32. Abdo AA, Karim HA, Al Fuhaid T, et al. Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Ann Saudi Med 2006; 26: 261-5.
33. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-93.
34. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
35. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
36. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-54.
37. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51: 890-7.
38. Frodsham AJ, Hill AV. Genetics of infectious diseases. Hum Mol Genet 2004; 2: R187-94.
39. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis 2011; 31: 115-27.
40. Clark PJ, Thompson AJ. Host genomics and HCV treatment response. J Gastroenterol Hepatol 2012; 27: 212-22.
41. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-7.
42. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012; 30: 88-106.
43. Zhang L, Jilg N, Shao RX, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55: 289-98.
44. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
45. Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-43.
46. Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55: 384-94.
47. Joshita S, Umemura T, Katsuyama Y, et al. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol 2012; 73: 298-300.
48. Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93: 644-9.
49. Li W, Jiang Y, Jin Q, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31: 1118-26.
50. Langhans B, Kupfer B, Braunschweiger I, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-65.
51. Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-6.
52. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
53. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-76.
54. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-20e1.
55. Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 2011; 54: 716-22.
56. Peng LJ, Guo JS, Zhang Z, et al. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens 2012; 79: 302-5.
57. Ren S, Lu J, Du X, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 2012; 61: 1433-9.
58. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.